<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />

<meta name="author" content="Johannes Cepicka" />


<title>Binary outcome variables</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>



<style type="text/css">
code {
white-space: pre;
}
.sourceCode {
overflow: visible;
}
</style>
<style type="text/css" data-origin="pandoc">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { display: inline-block; text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
{ counter-reset: source-line 0; }
pre.numberSource code > span
{ position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
{ content: counter(source-line);
position: relative; left: -1em; text-align: right; vertical-align: baseline;
border: none; display: inline-block;
-webkit-touch-callout: none; -webkit-user-select: none;
-khtml-user-select: none; -moz-user-select: none;
-ms-user-select: none; user-select: none;
padding: 0 4px; width: 4em;
color: #aaaaaa;
}
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa; padding-left: 4px; }
div.sourceCode
{ }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } 
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.at { color: #7d9029; } 
code span.bn { color: #40a070; } 
code span.bu { color: #008000; } 
code span.cf { color: #007020; font-weight: bold; } 
code span.ch { color: #4070a0; } 
code span.cn { color: #880000; } 
code span.co { color: #60a0b0; font-style: italic; } 
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.do { color: #ba2121; font-style: italic; } 
code span.dt { color: #902000; } 
code span.dv { color: #40a070; } 
code span.er { color: #ff0000; font-weight: bold; } 
code span.ex { } 
code span.fl { color: #40a070; } 
code span.fu { color: #06287e; } 
code span.im { color: #008000; font-weight: bold; } 
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.kw { color: #007020; font-weight: bold; } 
code span.op { color: #666666; } 
code span.ot { color: #007020; } 
code span.pp { color: #bc7a00; } 
code span.sc { color: #4070a0; } 
code span.ss { color: #bb6688; } 
code span.st { color: #4070a0; } 
code span.va { color: #19177c; } 
code span.vs { color: #4070a0; } 
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } 
</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    var j = 0;
    while (j < rules.length) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") {
        j++;
        continue;
      }
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') {
        j++;
        continue;
      }
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>




<style type="text/css">body {
background-color: #fff;
margin: 1em auto;
max-width: 700px;
overflow: visible;
padding-left: 2em;
padding-right: 2em;
font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;
font-size: 14px;
line-height: 1.35;
}
#TOC {
clear: both;
margin: 0 0 10px 10px;
padding: 4px;
width: 400px;
border: 1px solid #CCCCCC;
border-radius: 5px;
background-color: #f6f6f6;
font-size: 13px;
line-height: 1.3;
}
#TOC .toctitle {
font-weight: bold;
font-size: 15px;
margin-left: 5px;
}
#TOC ul {
padding-left: 40px;
margin-left: -1.5em;
margin-top: 5px;
margin-bottom: 5px;
}
#TOC ul ul {
margin-left: -2em;
}
#TOC li {
line-height: 16px;
}
table {
margin: 1em auto;
border-width: 1px;
border-color: #DDDDDD;
border-style: outset;
border-collapse: collapse;
}
table th {
border-width: 2px;
padding: 5px;
border-style: inset;
}
table td {
border-width: 1px;
border-style: inset;
line-height: 18px;
padding: 5px 5px;
}
table, table th, table td {
border-left-style: none;
border-right-style: none;
}
table thead, table tr.even {
background-color: #f7f7f7;
}
p {
margin: 0.5em 0;
}
blockquote {
background-color: #f6f6f6;
padding: 0.25em 0.75em;
}
hr {
border-style: solid;
border: none;
border-top: 1px solid #777;
margin: 28px 0;
}
dl {
margin-left: 0;
}
dl dd {
margin-bottom: 13px;
margin-left: 13px;
}
dl dt {
font-weight: bold;
}
ul {
margin-top: 0;
}
ul li {
list-style: circle outside;
}
ul ul {
margin-bottom: 0;
}
pre, code {
background-color: #f7f7f7;
border-radius: 3px;
color: #333;
white-space: pre-wrap; 
}
pre {
border-radius: 3px;
margin: 5px 0px 10px 0px;
padding: 10px;
}
pre:not([class]) {
background-color: #f7f7f7;
}
code {
font-family: Consolas, Monaco, 'Courier New', monospace;
font-size: 85%;
}
p > code, li > code {
padding: 2px 0px;
}
div.figure {
text-align: center;
}
img {
background-color: #FFFFFF;
padding: 2px;
border: 1px solid #DDDDDD;
border-radius: 3px;
border: 1px solid #CCCCCC;
margin: 0 5px;
}
h1 {
margin-top: 0;
font-size: 35px;
line-height: 40px;
}
h2 {
border-bottom: 4px solid #f7f7f7;
padding-top: 10px;
padding-bottom: 2px;
font-size: 145%;
}
h3 {
border-bottom: 2px solid #f7f7f7;
padding-top: 10px;
font-size: 120%;
}
h4 {
border-bottom: 1px solid #f7f7f7;
margin-left: 8px;
font-size: 105%;
}
h5, h6 {
border-bottom: 1px solid #ccc;
font-size: 105%;
}
a {
color: #0033dd;
text-decoration: none;
}
a:hover {
color: #6666ff; }
a:visited {
color: #800080; }
a:visited:hover {
color: #BB00BB; }
a[href^="http:"] {
text-decoration: underline; }
a[href^="https:"] {
text-decoration: underline; }

code > span.kw { color: #555; font-weight: bold; } 
code > span.dt { color: #902000; } 
code > span.dv { color: #40a070; } 
code > span.bn { color: #d14; } 
code > span.fl { color: #d14; } 
code > span.ch { color: #d14; } 
code > span.st { color: #d14; } 
code > span.co { color: #888888; font-style: italic; } 
code > span.ot { color: #007020; } 
code > span.al { color: #ff0000; font-weight: bold; } 
code > span.fu { color: #900; font-weight: bold; } 
code > span.er { color: #a61717; background-color: #e3d2d2; } 
</style>




</head>

<body>




<h1 class="title toc-ignore">Binary outcome variables</h1>
<h4 class="author">Johannes Cepicka</h4>



<p>Suppose we are planning a drug development program testing the
superiority of an experimental treatment over a control treatment. Our
drug development program consists of an exploratory phase II trial which
is, in case of promising results, followed by a confirmatory phase III
trial.</p>
<p>The drugdevelopR package enables us to optimally plan such programs
using a utility-maximizing approach. To get a brief introduction, we
presented a very basic example on how the package works in <a href="https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html">Introduction
to planning phase II and phase III trials with drugdevelopR</a>. In the
introduction, the observed outcome variable “tumor growth” was normally
distributed. However, the drugdevelopR package is not only restricted to
normally distributed outcome variables but also binary distributed
outcome variables and a time-to-event outcome variables. In this article
we want explain how the setting with binary distributed variables
works.</p>
<div id="the-example-setting" class="section level1">
<h1>The example setting</h1>
<p>Suppose we are developing a new treatment to prevent strokes,
<em>exper</em>. The patient variable that we want to investigate is if
the patient experienced a stroke (unfavorable outcome with value 1) or
not (favourable outcome with value 0) over a pre-defined observation
period. This is a binary outcome variable.</p>
<p>Within our drug development program, we will compare our experimental
treatment <em>exper</em> to the control treatment <em>contro</em>. The
treatment effect measure is given by <span class="math inline">\(\rho =
−\log(RR)\)</span>, which is the negative logarithm of the risk ratio
(relative risk) <span class="math inline">\(RR =
\frac{p_1}{p_0}\)</span>. Here, <span class="math inline">\(p_1\)</span>
is the failure probability of the experimental treatment (i.e. <span class="math inline">\(\mathbb{P}(X_i = 1|\text{experimental})\)</span>,
the probability that patient <span class="math inline">\(i\)</span> has
a stroke) and analogously <span class="math inline">\(p_0\)</span> is
the failure probability of the control treatment.</p>
</div>
<div id="applying-the-package-to-the-example" class="section level1">
<h1>Applying the package to the example</h1>
<p>After installing the package according to the <a href="https://sterniii3.github.io/drugdevelopR/#Installation">installation
instructions</a>, we can load it using the following code:</p>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" tabindex="-1"></a><span class="fu">library</span>(drugdevelopR)</span></code></pre></div>
<div id="defining-all-necessary-parameters" class="section level2">
<h2>Defining all necessary parameters</h2>
<p>In order to apply the package to the setting from our example, we
need to specify the following parameters:</p>
<ul>
<li><code>p11</code> is the assumed true probability that the
unfavorable outcome occurs for our experimental treatment
<em>exper</em>. <code>p0</code> is the assumed true probability that the
unfavorable outcome occurs for our control treatment <em>contro</em>.
Let’s assume that 30% of patients in the experimental group have a
stroke and 50% in the control group. Therefore, we set
<code>p11 = 0.3</code> and <code>p0 = 0.5</code>. For now, we will
assume that the probabilities are fixed and independent of any prior
distribution. Thus, we will set <code>fixed = TRUE</code>.</li>
<li><code>n2min</code> and <code>n2max</code> specify the minimal and
maximal number of participants for the phase II trial. The package will
search for the optimal sample size within this region. For now, we want
the program to search for the optimal sample size in the interval
between 20 and 400 participants. In addition, we will tell the program
to search this region in steps of four participants at a time by setting
<code>stepn2 = 4</code>.</li>
<li><code>rrgomin</code> and <code>rrgomax</code> specify the minimal
and maximal threshold value for the go/no-go decision rule in terms of
the negative logarithm of the risk ratio. The package will search for
the optimal threshold value within this region. For now, we want the
program to search in the interval between 0.7 and 0.9 while going in
steps of <code>steprrgo = 0.01</code>. Note that the lower bound of the
decision rule represents the smallest size of treatment effect observed
in phase II allowing to go to phase III, so it can be used to model the
minimal clinically relevant effect size. Moreover, note that the
interval specified above corresponds to the set <span class="math inline">\(\{-\log(0.9), ..., -\log(0.7)\}\)</span>.</li>
<li><code>c02</code> and <code>c03</code> are fixed costs for phase II
and phase III, respectively. We will set the phase II costs to 100 and
the phase III costs to 150 (in <span class="math inline">\(10^5\)</span>$), i.e. we have fixed costs of 10
000 000$ in phase II and 15 000 000$ in phase III. Note that the
currency of the input values does not matter, so an input value for
<code>c02</code> of 15 could also be interpreted as fixed costs of 1 500
000€ if necessary.</li>
<li><code>c2</code> and <code>c3</code> are the per-patient costs in
phase II and phase III. We will set them to be 0.75 in phase II and 0.1
in phase III. Again, these values are given in <span class="math inline">\(10^5\)</span>$, i.e. we have per-patient costs of
75 000$ in phase II and 100 000$ in phase III.</li>
<li><code>b1</code>, <code>b2</code> and <code>b3</code> are the
expected small, medium and large benefit categories for successfully
launching the treatment on the market for each effect size category in
<span class="math inline">\(10^5\)</span>$. We will define a small
benefit of 1000, a medium benefit of 2000, and a large benefit of 3000.
The effect size categories directly correspond to the treatment effect:
For example, if the treatment effect is between 1 and 0.95 (in terms of
the risk ratio) we have a small treatment effect yielding an expected
benefit of 100 000 000$.</li>
<li><code>alpha</code> is the specified significance level. We will set
<code>alpha = 0.025</code>.</li>
<li>1 - <code>beta</code> is the minimal power that we require for our
drug development program. We will set <code>beta = 0.1</code>, meaning
that we require a power of 90%.</li>
</ul>
<p>As in the setting with normally distributed outcomes, the treatment
effect may be fixed (as in this example) or may be distributed with
respect to a <a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html">prior
distribution</a>. Furthermore, <a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html">all
options</a> to adapt the program to your specific needs are also
available in this setting.</p>
<p>Now that we have defined all parameters needed for our example, we
are ready to feed them to the package. We will use the function
<code>optimal_binary()</code>, which calculates the optimal sample size
and the optimal threshold value for a binary distributed outcome
variable.</p>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" tabindex="-1"></a>res <span class="ot">&lt;-</span> <span class="fu">optimal_binary</span>(<span class="at">p0 =</span> <span class="fl">0.5</span>, <span class="at">p11 =</span>  <span class="fl">0.3</span>,               <span class="co"># probabilities of the unfavorable outcome</span></span>
<span id="cb2-2"><a href="#cb2-2" tabindex="-1"></a>   <span class="at">n2min =</span> <span class="dv">20</span>, <span class="at">n2max =</span> <span class="dv">400</span>, <span class="at">stepn2 =</span> <span class="dv">4</span>,                   <span class="co"># define optimization set for n2</span></span>
<span id="cb2-3"><a href="#cb2-3" tabindex="-1"></a>   <span class="at">rrgomin =</span> <span class="fl">0.7</span>, <span class="at">rrgomax =</span> <span class="fl">0.9</span>, <span class="at">steprrgo =</span> <span class="fl">0.01</span>,         <span class="co"># define optimization set for RRgo</span></span>
<span id="cb2-4"><a href="#cb2-4" tabindex="-1"></a>   <span class="at">alpha =</span> <span class="fl">0.025</span>, <span class="at">beta =</span> <span class="fl">0.1</span>,                              <span class="co"># drug development planning parameters</span></span>
<span id="cb2-5"><a href="#cb2-5" tabindex="-1"></a>   <span class="at">c2 =</span> <span class="fl">0.75</span>, <span class="at">c3 =</span> <span class="dv">1</span>, <span class="at">c02 =</span> <span class="dv">100</span>, <span class="at">c03 =</span> <span class="dv">150</span>,               <span class="co"># define fixed and variable costs for phase II and III,</span></span>
<span id="cb2-6"><a href="#cb2-6" tabindex="-1"></a>   <span class="at">K =</span> <span class="cn">Inf</span>, <span class="at">N =</span> <span class="cn">Inf</span>, <span class="at">S =</span> <span class="sc">-</span><span class="cn">Inf</span>,                            <span class="co"># constraints</span></span>
<span id="cb2-7"><a href="#cb2-7" tabindex="-1"></a>   <span class="at">steps1 =</span> <span class="dv">1</span>, <span class="at">stepm1 =</span> <span class="fl">0.95</span>,  <span class="at">stepl1 =</span> <span class="fl">0.85</span>,             <span class="co"># treatment effect size categories as proposed by IQWiG (2016)</span></span>
<span id="cb2-8"><a href="#cb2-8" tabindex="-1"></a>   <span class="at">b1 =</span> <span class="dv">1000</span>, <span class="at">b2 =</span> <span class="dv">2000</span>, <span class="at">b3 =</span> <span class="dv">3000</span>,                       <span class="co"># expected benefit categories</span></span>
<span id="cb2-9"><a href="#cb2-9" tabindex="-1"></a>   <span class="at">w =</span> <span class="fl">0.3</span>, <span class="at">p12 =</span> <span class="fl">0.5</span>, <span class="at">in1 =</span> <span class="dv">30</span>, <span class="at">in2 =</span> <span class="dv">60</span>,                <span class="co"># prior (https://web.imbi.uni-heidelberg.de/prior/)</span></span>
<span id="cb2-10"><a href="#cb2-10" tabindex="-1"></a>   <span class="at">gamma =</span> <span class="dv">0</span>,                                             <span class="co"># population structures in phase II and III</span></span>
<span id="cb2-11"><a href="#cb2-11" tabindex="-1"></a>   <span class="at">fixed =</span> <span class="cn">TRUE</span>,                                          <span class="co"># choose if true treatment effects are fixed or random</span></span>
<span id="cb2-12"><a href="#cb2-12" tabindex="-1"></a>   <span class="at">skipII =</span> <span class="cn">FALSE</span>,                                        <span class="co"># choose if skipping phase II would be an option</span></span>
<span id="cb2-13"><a href="#cb2-13" tabindex="-1"></a>   <span class="at">num_cl =</span> <span class="dv">1</span>)</span></code></pre></div>
</div>
<div id="interpreting-the-output" class="section level2">
<h2>Interpreting the output</h2>
<p>After setting all these input parameters and running the function,
let’s take a look at the output of the program.</p>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" tabindex="-1"></a>res</span>
<span id="cb3-2"><a href="#cb3-2" tabindex="-1"></a><span class="co">#&gt; Optimization result:</span></span>
<span id="cb3-3"><a href="#cb3-3" tabindex="-1"></a><span class="co">#&gt;  Utility: 1399.56</span></span>
<span id="cb3-4"><a href="#cb3-4" tabindex="-1"></a><span class="co">#&gt;  Sample size:</span></span>
<span id="cb3-5"><a href="#cb3-5" tabindex="-1"></a><span class="co">#&gt;    phase II: 260, phase III: 346, total: 606</span></span>
<span id="cb3-6"><a href="#cb3-6" tabindex="-1"></a><span class="co">#&gt;  Probability to go to phase III: 0.99</span></span>
<span id="cb3-7"><a href="#cb3-7" tabindex="-1"></a><span class="co">#&gt;  Total cost:</span></span>
<span id="cb3-8"><a href="#cb3-8" tabindex="-1"></a><span class="co">#&gt;    phase II: 295, phase III: 494, cost constraint: Inf</span></span>
<span id="cb3-9"><a href="#cb3-9" tabindex="-1"></a><span class="co">#&gt;  Fixed cost:</span></span>
<span id="cb3-10"><a href="#cb3-10" tabindex="-1"></a><span class="co">#&gt;    phase II: 100, phase III: 150</span></span>
<span id="cb3-11"><a href="#cb3-11" tabindex="-1"></a><span class="co">#&gt;  Variable cost per patient:</span></span>
<span id="cb3-12"><a href="#cb3-12" tabindex="-1"></a><span class="co">#&gt;    phase II: 0.75, phase III: 1</span></span>
<span id="cb3-13"><a href="#cb3-13" tabindex="-1"></a><span class="co">#&gt;  Effect size categories (expected gains):</span></span>
<span id="cb3-14"><a href="#cb3-14" tabindex="-1"></a><span class="co">#&gt;   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000)</span></span>
<span id="cb3-15"><a href="#cb3-15" tabindex="-1"></a><span class="co">#&gt;  Success probability: 0.83</span></span>
<span id="cb3-16"><a href="#cb3-16" tabindex="-1"></a><span class="co">#&gt;  Joint probability of success and observed effect of size ... in phase III:</span></span>
<span id="cb3-17"><a href="#cb3-17" tabindex="-1"></a><span class="co">#&gt;    small: 0.06, medium: 0.18, large: 0.59</span></span>
<span id="cb3-18"><a href="#cb3-18" tabindex="-1"></a><span class="co">#&gt;  Significance level: 0.025</span></span>
<span id="cb3-19"><a href="#cb3-19" tabindex="-1"></a><span class="co">#&gt;  Targeted power: 0.9</span></span>
<span id="cb3-20"><a href="#cb3-20" tabindex="-1"></a><span class="co">#&gt;  Decision rule threshold: 0.86 [RRgo] </span></span>
<span id="cb3-21"><a href="#cb3-21" tabindex="-1"></a><span class="co">#&gt;  Assumed true effect:</span></span>
<span id="cb3-22"><a href="#cb3-22" tabindex="-1"></a><span class="co">#&gt;   rate in the control: 0.5, rate in the treatment group: 0.3</span></span>
<span id="cb3-23"><a href="#cb3-23" tabindex="-1"></a><span class="co">#&gt;  Treatment effect offset between phase II and III: 0 [gamma]</span></span></code></pre></div>
<p>The program returns a total of thirteen values and the input values.
For now, we will only look at the most important ones:</p>
<ul>
<li><code>res$n2</code> is the optimal sample size for phase II and
<code>res$n3</code> the resulting sample size for phase III. We see that
the optimal scenario requires 260 participants in phase II and 346
participants in phase III.</li>
<li><code>res$RRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a risk ratio of less than
0.86 in phase II in order to proceed to phase III.</li>
<li><code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
1399.56, i.e. we have an expected utility of 139 956 000$.</li>
</ul>
</div>
</div>
<div id="where-to-go-from-here" class="section level1">
<h1>Where to go from here</h1>
<p>In this article we introduced the setting, when the outcome variable
is binary distributed. For more information on how to use the package,
see:</p>
<ul>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/Introduction-to-drugdevelopR.html"><em>Introduction
to drugdevelopR:</em></a> See how the package works in a basic normally
distributed example.</li>
<li><em>Different outcomes:</em> Apply it to <a href="https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html">time-to-event
endpoints</a>.</li>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html"><em>Interpreting
the rest of the output:</em></a> Obtain further details on your drug
development program.</li>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html"><em>Fixed
or prior:</em></a> Model the assumed treatment effect on a prior
distribution.</li>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html"><em>More
parameters:</em></a> Define custom effect size categories. Put
constraints on the optimization by defining maximum costs, the total
expected sample size of the program or the minimum expected probability
of a successful program. Define an expected difference in treatment
effect between phase II and III. Skip phase II.</li>
<li><em>Complex drug development programs:</em> Adapt to situations with
<a href="https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html">biased
effect estimators</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html">multiple
phase III trials</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multiarm_Trials.html">multi-arm
trials</a>, or <a href="https://sterniii3.github.io/drugdevelopR/articles/Multiple_Endpoints.html">multiple
endpoints</a>.</li>
<li><a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html#parallel-computing"><em>Parallel
computing:</em></a> Be faster at calculating the optimum by using
parallel computing.</li>
</ul>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
